iBio, Inc. (IBIO)
iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bio analytic services. iBio, Inc. has a license agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases; collaboration agreement with The Texas A&M University System for the development of coronavirus disease 2019 vaccine candidates; license agreement with the University of Natural Resources and Life Sciences, Vienna; and collaboration agreement with CC-Pharming Ltd. The company is headquartered in Bryan, Texas.
$15.44M
Dr. Martin B. Brenner D.V.M., Ph.D.
105.00
Bryan, TX
Aug 18, 2008
-0.25
$-7.23
0.29
1.69
-46,324.00%
-0.30
0.00
0.28
322.53
1.69
-46.18%
-147.88%
Similar stocks (9)
ADMA Biologics, Inc.
ADMA
BioCryst Pharmaceuticals, Inc.
BCRX
Ocugen, Inc.
OCGN
Vaxart, Inc.
VXRT
GeoVax Labs, Inc.
GOVX
Tonix Pharmaceuticals Holding Corp.
TNXP
Jaguar Health, Inc.
JAGX
Sonnet BioTherapeutics Holdings, Inc.
SONN
Palisade Bio, Inc.
PALI
ETF Exposure (3)
Dimensional U.S. Targeted Value ETF
DFAT
8.402e-5%
Vanguard Extended Market Index Fund Institutional Shares
VIEIX
0%
Vanguard Extended Market Index Fund
VXF
0%
Similar stocks (9)
ADMA Biologics, Inc.
ADMA
BioCryst Pharmaceuticals, Inc.
BCRX
Ocugen, Inc.
OCGN
Vaxart, Inc.
VXRT
GeoVax Labs, Inc.
GOVX
Tonix Pharmaceuticals Holding Corp.
TNXP
Jaguar Health, Inc.
JAGX
Sonnet BioTherapeutics Holdings, Inc.
SONN
Palisade Bio, Inc.
PALI
ETF Exposure (3)
Dimensional U.S. Targeted Value ETF
DFAT
8.402e-5%
Vanguard Extended Market Index Fund Institutional Shares
VIEIX
0%
Vanguard Extended Market Index Fund
VXF
0%